Gabelli Funds LLC Takes Position in Abivax SA Sponsored ADR $ABVX

Gabelli Funds LLC purchased a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 4th quarter, HoldingsChannel reports. The firm purchased 4,950 shares of the company’s stock, valued at approximately $668,000.

Several other large investors also recently bought and sold shares of ABVX. UBS Group AG increased its holdings in Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares during the period. Darwin Global Management Ltd. purchased a new stake in Abivax during the 3rd quarter worth about $263,698,000. Paradigm Biocapital Advisors LP purchased a new stake in Abivax during the 3rd quarter worth about $132,800,000. TCG Crossover Management LLC increased its holdings in Abivax by 17.4% during the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after purchasing an additional 1,055,000 shares during the period. Finally, Vestal Point Capital LP purchased a new stake in Abivax during the 3rd quarter worth about $84,900,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ABVX shares. Barclays upped their price target on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Wall Street Zen raised shares of Abivax from a “sell” rating to a “hold” rating in a research report on Saturday. BTIG Research reiterated a “buy” rating and set a $150.00 target price on shares of Abivax in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a report on Monday, April 20th. Finally, Oddo Bhf restated an “outperform” rating on shares of Abivax in a research note on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Abivax presently has a consensus rating of “Moderate Buy” and a consensus target price of $137.15.

Abivax Price Performance

Abivax stock opened at $121.99 on Friday. Abivax SA Sponsored ADR has a 1-year low of $5.59 and a 1-year high of $148.83. The stock has a market cap of $9.72 billion, a PE ratio of -23.41 and a beta of 0.84. The stock’s fifty day moving average is $117.74 and its two-hundred day moving average is $118.98.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Monday, May 25th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. On average, research analysts expect that Abivax SA Sponsored ADR will post -3.84 earnings per share for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.